A Four-Year Retrospective Analysis (2021–2024): The Impact of Prior Antibiotic Exposure on CRE Infection Prevalence and Antibiogram Profiles in a Tertiary Care Setting
This four-year retrospective study in a tertiary care setting in Chattogram, Bangladesh, reveals that prior antibiotic exposure, particularly to carbapenems and cephalosporins, is strongly associated with the emergence of multidrug-resistant CRE infections, while identifying colistin and tigecycline as the most effective remaining therapeutic options against a pathogen that carries a high mortality rate.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the microscopic world inside the human body, bacteria are constantly evolving, but they do not evolve in a vacuum. They respond to the environment we create for them, particularly the medicines we use to fight them. When doctors prescribe antibiotics, the drugs kill the weak bacteria, but if a few possess natural defenses, those survivors multiply and take over. This process, known as selective pressure, means that the more we use antibiotics, the more we train bacteria to resist them. A particularly dangerous group of these survivors is called carbapenem-resistant Enterobacteriaceae. These are bacteria that have learned to ignore carbapenems, a powerful class of drugs often considered the last line of defense against serious infections. When these last-resort drugs fail, the treatment options shrink dramatically, leading to longer hospital stays and a higher risk of death. Understanding how these bacteria emerge and how they respond to different drugs is critical for doctors who must choose the right treatment before lab results are even available.
In a four-year study conducted at a major hospital in Chattogram, Bangladesh, researchers set out to map the landscape of these dangerous infections. They looked back at records from over 15,000 patients seen between 2021 and 2024 to find those who had developed a confirmed infection with these resistant bacteria. They found 113 such cases, which translates to roughly seven cases for every 1,000 patients observed. The team did not just count the cases; they dug deep into the medical history of each patient to see what antibiotics they had taken in the month before their infection appeared. They also tested the bacteria they found to see exactly which drugs could still kill them and which ones the bacteria could shrug off.
The most striking discovery was how common prior antibiotic use was among the infected patients. Nearly 87 percent of the people with these resistant infections had taken at least one type of antibiotic in the month before they got sick. The researchers noticed a clear pattern: the more different types of antibiotics a patient had taken, the more likely the bacteria were to be resistant to multiple drugs. If a patient had taken no antibiotics, the bacteria were not multidrug-resistant. If they had taken one or two types, the bacteria were still not resistant to multiple drugs. However, once a patient had taken three or four different classes of antibiotics, the chance of the bacteria being resistant to many drugs jumped significantly. For those who had taken all five major classes of antibiotics tracked in the study, more than half of the bacteria were multidrug-resistant. This suggests that the breadth of exposure, rather than just the duration of a single treatment, is a powerful driver of resistance.
When the scientists tested the bacteria against a wide range of medicines, the results painted a grim picture for standard treatments. The bacteria were almost universally resistant to common drugs like cephalosporins and fluoroquinolones, with resistance rates exceeding 84 percent for many of them. Even the powerful carbapenem drugs, which are usually the final hope, failed to work against 77 percent of the bacteria tested. This means that doctors in this region can no longer rely on these standard drugs to treat suspected infections empirically, or before knowing the specific bug. Instead, the study identified two older drugs, colistin and tigecycline, as the most effective remaining options, with the majority of bacteria still susceptible to them. However, the researchers noted that these drugs must be used carefully and targeted to the specific type of bacteria, as resistance patterns varied between different species.
The study also looked at who survived the infection and who did not. In this group of patients, about 29 percent died in the hospital. Interestingly, the data showed that patients who had taken antibiotics before their infection were actually less likely to die than those who had not. This might seem counterintuitive, as one might assume that prior antibiotic use would make the infection worse. However, the researchers explained that this was not because the antibiotics protected the patients. Instead, it was because patients who had taken antibiotics were usually those who had already been in contact with the healthcare system. They arrived at the hospital earlier in their illness and were under medical supervision sooner, whereas those who had not taken antibiotics often arrived very late, when they were already critically ill. The study explicitly ruled out the idea that taking antibiotics beforehand offers any biological protection against these infections.
Ultimately, this research provides a clear warning and a set of practical guidelines for the region. It confirms that the widespread use of multiple types of antibiotics is directly linked to the rise of bacteria that resist almost everything. The data suggests that doctors should stop using common antibiotics like cephalosporins and fluoroquinolones as a first guess for serious infections in patients who have recently been in contact with healthcare. Instead, they should reserve the remaining effective drugs for when they are absolutely necessary and use them only when they know exactly which bacteria they are fighting. By understanding that the number of different antibiotics a patient has seen is a strong warning sign for resistance, medical teams can make smarter, safer choices that might slow down the spread of these superbugs.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.